Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gutffin Plus is an oral laxative suspension developed by ARB Remedies for the treatment of constipation. It is a combination product containing sodium picosulfate, liquid paraffin, and magnesium hydroxide (Milk of Magnesia). Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria into its active metabolite, which then stimulates the intestinal mucosa to increase peristalsis. Liquid paraffin acts as a lubricant laxative, softening the stool and coating the intestinal wall to facilitate easier passage. Magnesium hydroxide is an osmotic laxative that draws water into the intestinal lumen, increasing stool volume and softening its consistency. Together, these three components provide a synergistic effect to relieve both acute and chronic constipation by addressing stool consistency, lubrication, and bowel movement frequency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gutffin Plus.